Almirall: stock up after clinical trial results

(CercleFinance.com) - Almirall shares are up over 4% in Madrid after the dermatology company announced positive data from two Phase III trials of Lebrikizumab in moderate-to-severe atopic dermatitis (AD).


The Spanish company said that in these pivotal Advocate1 and Advocate2 trials, the product led to significant improvements, with at least 75% skin clearance in over half of people with moderate-to-severe AD.

Lebrikizumab also met key secondary endpoints, including early onset of skin clearance and relief of itching, with reduced itch interference in quality of sleep and life.


Copyright (c) 2021 CercleFinance.com. All rights reserved.